Analysts Anticipate Neon Therapeutics Inc (NASDAQ:NTGN) Will Post Earnings of -$0.65 Per Share

Analysts forecast that Neon Therapeutics Inc (NASDAQ:NTGN) will report ($0.65) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Neon Therapeutics’ earnings. The highest EPS estimate is ($0.42) and the lowest is ($0.76). Neon Therapeutics posted earnings per share of ($0.84) in the same quarter last year, which suggests a positive year-over-year growth rate of 22.6%. The business is expected to issue its next quarterly earnings report on Monday, March 9th.

On average, analysts expect that Neon Therapeutics will report full year earnings of ($2.54) per share for the current financial year, with EPS estimates ranging from ($3.01) to ($1.71). For the next year, analysts expect that the firm will post earnings of ($1.60) per share, with EPS estimates ranging from ($2.86) to ($1.02). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.04).

A number of equities research analysts have recently commented on NTGN shares. Bank of America cut shares of Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th. HC Wainwright cut shares of Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 27th. Mizuho dropped their price objective on shares of Neon Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Zacks Investment Research cut shares of Neon Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 29th. Finally, Morgan Stanley cut shares of Neon Therapeutics from an “overweight” rating to a “sell” rating in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $10.58.

In related news, insider Richard Gaynor sold 22,322 shares of Neon Therapeutics stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $1.24, for a total value of $27,679.28. Following the sale, the insider now owns 201,822 shares of the company’s stock, valued at approximately $250,259.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 38.93% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new stake in Neon Therapeutics in the 3rd quarter valued at $361,000. Vanguard Group Inc. grew its stake in Neon Therapeutics by 3.6% in the 2nd quarter. Vanguard Group Inc. now owns 612,398 shares of the company’s stock valued at $2,903,000 after acquiring an additional 21,387 shares during the period. BlackRock Inc. grew its stake in Neon Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock valued at $3,631,000 after acquiring an additional 79,729 shares during the period. Bank of New York Mellon Corp grew its stake in Neon Therapeutics by 112.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 71,443 shares of the company’s stock valued at $339,000 after acquiring an additional 37,755 shares during the period. Finally, Northern Trust Corp grew its stake in Neon Therapeutics by 8.5% in the 2nd quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock valued at $789,000 after acquiring an additional 12,971 shares during the period. 58.19% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ NTGN traded down $0.07 during midday trading on Wednesday, reaching $1.00. 673,569 shares of the stock were exchanged, compared to its average volume of 277,765. The firm has a market cap of $32.31 million, a price-to-earnings ratio of -0.18 and a beta of 1.32. Neon Therapeutics has a twelve month low of $0.98 and a twelve month high of $7.51. The firm has a 50-day simple moving average of $1.76 and a two-hundred day simple moving average of $3.09. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 0.15.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Read More: Why is the LIBOR significant?

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.